

Eritrea Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Eritrea					
2. Grant number: 1821-ERI-18e-X; 18-ERI-18d-X; 18-ERI-08m-Y; 18-ERI-35b-Y					
3. Date of Decision Letter: 6 March 2019					
4. Date of the Partnership Framework Agreement: 16 April 2013					
5. Programme title: New Vaccine Support (NVS), Measles-Rubella first and second dose routine and Measles-Rubella catch-up campaign					
6. Vaccine type: Measles-Rubella					
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED					
8. Programme duration¹: 2018 - 2021					
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)					
	2018	2019	2020	2021	Total ²
Programme Budget - Routine (US\$)	US\$32,500	US\$96,500	US\$110,000	US\$116,000	US\$355,000
Programme Budget - Campaign (US\$)	US\$1,180,500				US\$1,180,500
Programme Budget - TOTAL (US\$)	US\$1,213,000	US\$96,500	US\$110,000	US\$116,000	US\$1,535,500
10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³					
Type of supplies to be purchased with Gavi funds in each year (Routine)		2018	2019		
Number of Measles-Rubella vaccines doses			148,100		
Annual Amounts (US\$)		US\$32,500	US\$96,500		
Type of supplies to be purchased with Gavi funds in each year (Campaign)					
Annual Amounts (US\$)		US\$1,180,500			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

12. Self-procurement: N/A

13. Co-financing obligations for routine: Reference code: 1821-ERI-18e-X-C According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020	2021
Number of vaccine doses	126,600	144,100	151,800
Value of vaccine doses (US\$)	US\$80,986	US\$92,191	US\$97,127
Total co-financing payments (US\$) (including freight)	US\$82,500	US\$94,000	US\$99,000

14. Co-financing obligations for campaign: Not applicable

15. Vaccine introduction grant (in US\$): US\$ 99,964 disbursed on 23 March 2018

16. Operational support for campaigns: US\$ 1,015,300 disbursed on 23 March 2018

17. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign	Within 3 months of end of campaign
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign	As soon as available
18. Financial clarifications: N/A	
19. Other conditions: As a condition to Gavi's support for measles and rubella, country will be required to fully self-finance with domestic resources the measles component of the first dose of measles containing vaccine (MCV1) in its national immunisation programme for 2018 and onwards.	

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

6 March 2019